A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...
Abstract: Enhancing power grid resilience through improved analysis and planning of Distributed Energy Resources is a key for power system planner. This paper explores the integration of Causal Loop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback